Table 2 Hazard Ratios and 95% CIs for 5-years DFS, 5-years DMFS and 5-years BCSS by age group.

From: The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer

a. Hazard Ratios and 95% CIs for 5-years DFS by age group

Age group (years)

patient N (%)

5-years DFS N (%)

HR (95% CI)

HR (95% CI)*

≤40

542

339 (62.5)

1.45 (1.20 to 1.76)

1.37 (1.12 to 1.67)

41–50

759

551 (72.6)

1.00 (REF)

1.00 (REF)

51–60

555

381 (68.6)

1.18 (0.96 to 1.44)

1.06 (0.85 to 1.31)

>60

269

177 (65.8)

1.37 (0.99 to 1.62)

1.20 (0.92 to 1.58)

b. Hazard Ratios and 95% CIs for 5-years DMFS by age group

Age group (years)

patient N (%)

5-years DMFS, N (%)

HR (95%CI)

HR (95% CI)*

≤40

542

352 (64.9)

1.45 (1.19 to 1.77)

1.38 (1.12 to 1.69)

41–50

759

565 (74.4)

1.00 (REF)

1.00 (REF)

51–60

555

394 (71.0)

1.16 (0.94 to 1.43)

1.05 (0.84 to 1.31)

>60

269

180 (66.9)

1.33 (1.03 to 1.70)

1.23 (0.93 to 1.63)

c. Hazard Ratios and 95% CIs for 5-years BCSS by age group

Age group (years)

patient N (%)

5-years BCSS N (%)

HR (95% CI)

HR (95% CI)*

≤40

542

460 (84.9)

1.48 (1.09 to 2.01)

1.37 (1.00 to 1.89)

41–50

759

679 (89.5)

1.00 (REF)

1.00 (REF)

51–60

555

479 (86.3)

1.33 (0.97 to 1.82)

1.15 (0.82 to 1.60)

>60

269

231 (85.9)

1.37 (0.93 to 2.01)

1.42 (0.94 to 2.15)

  1. Abbreviations: HR, hazard ratios; DFS, disease-free survival; REF, reference.
  2. Abbreviations: DMFS, distant metastasis-free survival.
  3. Abbreviations: BCSS, breast cancer special-survival.
  4. *Adjusted for tumor stage, histological grade, chemotherapy, endocrine-therapy, trastuzumab and molecular subtype.